Recent reports had shown that MCL-1 was over-expressed in several tumors, including chronic myeloid leukemia, lung cancer, and hepatocellular carcinoma [37–40], suggesting that MCL-1 may participate in the tumor initiation and can be a potential therapeutic target in the treatment of several human malignancies. The gene discussed is MCL1; the disease is lung carcinoma.